Compare GSK plc (GSK) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs IQIYI Inc - ADR — how do they compare? GSK plc trades at $46.6 (market cap $91.88B), while IQIYI Inc - ADR trades at $1.02 (market cap $974.67M). The key difference: GSK plc is far larger — about 94.3× IQIYI Inc - ADR's market cap, and GSK plc pays a 3.9% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and IQIYI Inc - ADR for 55 Days on average.
| GSK | IQ | |
|---|---|---|
Market Cap | $91.88B | $974.67M |
Volume | 7,730,529 | 4,964,108 |
Sector | Health | Media |
52-Week High | $61.18 | $2.35 |
52-Week Low | $43.24 | $0.86 |
Typical Hold Time | 93 Days | 55 Days |
Enterprise Value | $111.88B | $2.47B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
IQ trades at $1.025, up 0.99% today, but technicals are bearish with mixed sentiment. The company reported a net loss of $206.31M in 2025 despite beating EPS estimates in recent quarters. Revenue declined to $27.29B, and profitability metrics like ROE are negative. Analyst consensus is split with 50% buy ratings, but cash flow trends show volatility, and the firm is heavily investing in AI-driven content.
Outlook is cautious; while AI initiatives offer growth potential, core streaming pressures and persistent losses pose risks. The stock's low P/S and P/B suggest undervaluation, but investor confidence hinges on a return to profitability and successful execution of new content strategies amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
